POLLARD, JOHN R.,波拉德 约翰R,波拉德 約翰R,REAPER, PHILIP M.,瑞普 菲利浦M,HAMMOND, ESTER M.,哈蒙 伊斯特M,ASMAL, MOHAMMED,艾斯莫 穆罕默德,波拉德 约翰R,波拉德 約翰R,瑞普 菲利浦M,哈蒙 伊斯特M,艾斯莫 穆罕默德
申请号:
TW106107579
公开号:
TW201740949A
申请日:
2013.04.08
申请国别(地区):
TW
年份:
2017
代理人:
摘要:
The present invention relates to compounds useful as inhibitors of ATR protein kinase and combination therapies thereof. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.The compounds of this invention have formula I: wherein the variables are as defined herein.本發明係關於用作ATR蛋白激酶抑制劑之化合物及其組合療法。本發明亦關於包含本發明化合物之醫藥上可接受之組合物;使用本發明化合物治療各種疾病、病症及病狀之方法;製備本發明化合物之方法;用於製備本發明化合物之中間體;及使用該等化合物於活體外應用(諸如激酶在生物學及病理學現象中之研究,該等激酶所介導之細胞內訊息傳導路徑之研究,及新激酶抑制劑之比較評估)之方法。本發明化合物具有式I:其中該等變量係如本文所定義。